# PT-141

Canonical source: https://retacompare.com/encyclopedia/pt-141

Non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). MC4R activation in the medial preoptic area drives sexual desire centrally.

Reference facts

Also known asBremelanotide, VyleesiCategorySexual Health & MSHMechanism of actionNon-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). MC4R activation in the medial preoptic area drives sexual desire centrally.TargetsMC4R, MC3R, MC1RIndications under research or approvedHypoactive Sexual Desire Disorder (HSDD) in pre-menopausal womenRegulatory status (reference entry)FDA-approved (2019)Half-life~2.7 hours (subcutaneous)Sequence notesCyclic heptapeptide Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH derived from α-MSH.Molecular weight (Da)1025Originator / sponsorAMAG / Palatin TechnologiesFirst reported2003
    Primary References

Vyleesi FDA label


    Explore research articles about PT-141


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Vyleesi FDA label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf